Clinical Trials Browser

Phase 1 × lumretuzumab × Breast × Clear all

NCT01918254 2017-09-12

A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein

Phase 1 Completed

Breast Neoplasms